Bioheart, Inc. to Present at Medtech Insight's 'Investment In Innovation' Conference.

SAN FRANCISCO -- Bioheart's Chairman and CEO, Howard J. Leonhardt, will be providing a presentation on its pioneering autologous cell-based therapy, MyoCell(TM), to repair and regenerate muscle in patients with heart disease. This presentation will also illustrate Bioheart's innovative method of delivering its therapy through a proprietary minimally-invasive injection catheter.

Bioheart, Inc. is focused on the discovery, development and commercialization of cell-based therapy products for the treatment of cardiovascular diseases such as congestive heart failure ("CHF") secondary to myocardial infarction ("MI") and cardiovascular electrical abnormalities. Bioheart believes that its products hold the potential to revolutionize the treatment of cardiovascular diseases and become a new standard of care by offering treatments that may improve cardiac function, are more cost-effective and are lower-risk than the current alternatives, which include heart transplantation, biventricular pacing, ventricular assist devices and certain drug therapies.

Bioheart's initial patient-derived ("autologous") cellular-based implant technology, MyoCell(TM), harvests specially selected cells from a patient's own thigh muscle and utilizes that raw material to produce uniquely composed implants that are placed into the heart either percutaneously (via cardiac catheter) or surgically. The MyoCell(TM) therapy is designed to regenerate infarcted, scarred or non-functioning myocardial tissue into functioning muscle that may contribute to increased global cardiac output and may slow down the progression of CHF. The MyoCell(TM) product has also demonstrated the potential to positively impact the heart muscle remodeling process. It is expected that the market for MyoCell(TM) will include anyone who has suffered from a heart attack.

Bioheart, Inc. is sponsoring clinical trials of its MyoCell(TM) myogenic cell composition delivered via the MyoCath(R) catheter for damaged heart muscle repair in the U.S.A. and Europe. In Europe, a Phase II clinical trial is currently underway using the MyoCell(TM) product at the Thorax Centre and the Cardiovascular Research Institute Maastricht in the Netherlands, Alst Hospital in Belgium, Universitat Rostock in Germany, Hospital Clinico San Carlos in Spain, and in England: St. Mary's Hospital, Imperial College and Royal Brompton Hospital. Bioheart is also currently enrolling patients in a Phase I study in the U.S. at five centers: Mount Sinai Hospital in New York, The Minneapolis Heart Institute, The American Cardiovascular Research Institute in Atlanta, The Cleveland Clinic and The Mayo Clinic in Rochester, Minnesota.

Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation" conference or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512, e-mail [e-mail], or visit www.medtechinsight.com.